Earnings ·
Reports Q3 net loss of $52.3M as FILSPARI sales jump 120% to $200M
TVTXTravere Therapeutics, Inc.
Travere Therapeutics reported a third-quarter GAAP net loss of $52.3 million, or $0.55 per share, compared to a net income of $25.7 million in the prior-year period. U.S. net product sales surged 120% year-over-year to $220.2 million, driven by FILSPARI revenue of $200.2 million. The company recognized a $113.1 million in-process research and development expense related to its licensing agreement for civorebrutinib. Cash, cash equivalents, and marketable securities totaled $471.8 million as of September 30, 2026. Travere Therapeutics is a biopharmaceutical company focused on developing and commercializing therapies for rare kidney diseases.